An Open Label, International, Multi-Center, Phase I/IIA Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed/Refractory Hodgkin Lymphoma, Mature T-Cell Lymphoma and Multiple Myeloma (RID Study)
Hodgkin's Lymphoma | Multiple Myeloma | Non-Hodgkin's Lymphoma
What is the purpose of this trial?
- To establish DLTs and an MTD for the combination of romidepsin and lenalidomide for patients with lymphoma; and of romidepsin, lenalidomide and dexamethasone for patients with myeloma.
- To establish tolerability and feasibility at the recommended phase-II doses for the combination regimens.
- To establish initial evidence of efficacy in each of the three treatment groups according to histological diagnosis.
- To explore the immunological, histological and gene-expression correlates of disease response and drug toxicity.
Click here for detailed information about who can participate in this trial.
- Celgene Corporation
Yale Cancer Center
- Last Updated:
- Study HIC#: